- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology
People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.
People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.
“Right now we are looking at progression-free, stable disease as almost a win,” she said.
Keeping that in mind, Michael Kolodziej, MD, expects the rules will change, although he is skeptical that non-traditional endpoints will start to be implemented. The way those would be used, he said, would be to distinguish one of the many PD-1, PD-L1 drugs from the others.
“I think patient-reported outcomes are sorely lacking from the vast majority of work that has been done in oncology,” Dr Kolodziej said. “If we could find a way to collect that data and tie it to other more traditional endpoints that would be a great service.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
